linjc16/ctgov huggingface dataset:
Prediction of Risk Factors for Adverse Events After Head and Neck Vascular Recanalization Surgery Based on Machine Learning Models

Study Overview
=================
Brief Summary
-----------------
Prediction of risk factors for adverse events after head and neck vascular recanalization surgery based on machine learning models

Official Title
-----------------
The Second Affiliated Hospital of Air Force Military Medical University

Conditions
-----------------
Machine Learning

Intervention / Treatment
-----------------
* Other: observe


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: (1) All enrolled patients were diagnosed with clear head and neck artery stenosis and a risk event after head and neck revascularization; (2) Location of lesion: origin of internal carotid artery, bifurcation of internal and external carotid arteries; (3) Patients with symptomatic head and neck artery stenosis and dangerous events after head and neck blood flow reconstruction, and with a degree of stenosis ≥ 70% on non-invasive examination or stenosis ≥ 50% found on angiography; (4) Asymptomatic head and neck artery stenosis and risk events after head and neck revascularization, with a degree of stenosis ≥ 70% on non-invasive examination or stenosis ≥ 60% found on angiography; (5) Asymptomatic head and neck artery stenosis and dangerous events after head and neck blood flow reconstruction, with a non-invasive examination of stenosis degree less than 70%, but angiography or other examinations indicate that the stenosis lesion is in an unstable state; (6) Symptomatic head and neck artery stenosis and risk events after head and neck revascularization, non-invasive examination of head and neck artery stenosis and risk events after head and neck revascularization are 50% to 69%; (7) Sign the project informed consent form Exclusion Criteria: (1) Patients with poor overall condition and intolerance to general anesthesia; (2) Patients with mental illness or severe mental illness; (3) Severe respiratory system diseases; (4) Pregnant and lactating women; (5) Participating in another clinical study; (6) Patients with advanced tumors or those who are expected to die within one year;

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| xi'an<br> | Other: observe<br>* observational study<br>|
| shanxi<br> | Other: observe<br>* observational study<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| death |  | one year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Recurrence of stroke |  | one year |
Tumor Deposits in Colorectal Cancers

Study Overview
=================
Brief Summary
-----------------
Tumor deposits (TDs) are emerging as an adverse prognostic factor in colorectal cancers (CRCs), but they are quite ignored in the current staging system. Previous proposals to incorporate TDs in node stage or consider them distant metastases raised some doubt. The Authors propose a new staging system to optimize treatments.

Detailed Description
-----------------
Tumor deposits (TDs) are emerging as an adverse prognostic factor in colorectal cancers (CRCs).In the current staging system TDs are somewhat neglected. It has been proposed to add TD count to the number of metastatic lymph nodes or to consider TDs as distant metastases, but the scientific basis of these proposals seems dubious and not supported by robust statistical analyses. The investigators supposed that splitting the three sub-stages of the stage III CRC according to absence or presence of TDs could be an easy and useful method to avoid the loss of crucial information. The proposed study will include 243 stage III CRC patients undergoing radical surgery and adjuvant chemotherapy. Each new substage, according to absence or presence of tumor deposits, will be analyzed with sophisticated statistical analysis (particularly the area-under-curve (AUC), calculated by the time-dependent receiver-operating-characteristic (ROC) curve for censored survival data) to individuate if this new staging does better the current one.

Official Title
-----------------
Presence of Tumor Deposits is a Strong Indicator of Poor Outcome in Stage III Colorectal Cancers Undergoing Radical Surgery: Need for an Urgent Revision of the Staging System

Conditions
-----------------
Extranodal Extension

Intervention / Treatment
-----------------
* Procedure: Colorectal Resection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: colorectal cancers in stage III TNM undergoing radical surgery and adjuvant chemotherapy Exclusion Criteria: Lynch syndrome Rectal Cancer undergoing neoadjuvant (radio)chemotherapy colorectal cancers without metastatic nodes metastatic colorectal cancers eligible patients refusing adjuvant chemotherapy
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Tumor Deposits<br>Colorectal cancers with and without tumor deposits, undergoing curative surgery and adjuvant chemotherapy | Procedure: Colorectal Resection<br>* Radical resection of colorectal cancer<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall Survival | 1 to 5 years overall survival | 5 years | 
| Disease-free Survival | 1 to 5 years disease-free survival | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
tumor deposits, colorectal cancers, TNM staging system, ROC Curve
Exercise CMR in (p)LF-LG AS

Study Overview
=================
Brief Summary
-----------------
Patient with paradoxical or conventional low-flow low-gradient aortic stenosis on echocardiographic assessment will undergo physiological exercise-stress CMR in addition to guideline recommended surveys prior to TAVR.

Official Title
-----------------
Exercise CMR in (Paradoxical) Low-flow Low-gradient Aortic Stenosis

Conditions
-----------------
Aortic Stenosis, Severe

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: paradoxical or conventional severe low-flow low-gradient aortic stenosis Exclusion Criteria: CMR incapable device unable to undergo 40 min scan (can not lie flat, claustrophobia) renal insufficiency (eGFR <30 ml/min/1.73m²) allergy against contrast agent unable to exercise in supine position

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| paradoxical LF-LG AS<br> | |
| conventional LF-LG AS<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Composite of events: number of participants with cardiovascular death or heart failure hospitalisation |  | 12 months |
Effect of H. Pylori Eradication on Alleviating Symptoms in Functional Dyspepsia Patients

Study Overview
=================
Brief Summary
-----------------
In patients with Helicobacter pylori-positive functional dyspepsia, long-term follow-up for 6 months after standard triple therapy first-line eradication treatment, the rate of symptom disappearance and degree of improvement of functional dyspepsia were confirmed through changes in symptom scores and changes in drug usage, and eradication treatment The purpose of this study is to confirm the rate of symptom disappearance according to the results.

Official Title
-----------------
Effect of H. Pylori Eradication on Alleviating Symptoms in Functional Dyspepsia Patients: A Multicenter, Comparative Study

Conditions
-----------------
Helicobacter Pylori-positive With Functional Dyspepsia

Intervention / Treatment
-----------------
* Drug: K-CAB


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male and female outpatients between the ages of 19 and 75 Who have symptoms of functional dyspepsia (early fullness, postprandial discomfort, epigastric pain, epigastric soreness) that correspond to Rome criteria 4 (diagnostic criteria questionnaire) Exclusion Criteria: Small intestine and large intestine disease within 6 months of the screening visit (Visit 1) liver, pancreatobiliary disease within 6 months of the screening visit (Visit 1) peptic ulcer within 6 months of the screening visit (Visit 1)

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Tegoprazan 50mg<br>single group | Drug: K-CAB<br>* Tegoprazan 50 mg 1 tab twice daily Amoxicillin 500mg 2 cap twice daily Clarithromycin 500mg 1tab twice daily<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of disappearance of dyspepsia symptoms | Rate of disappearance of dyspepsia symptoms after 6 months of eradication treatment | Day 176 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Improvement rate of dyspepsia symptoms | Change rate of dyspepsia symptoms after 3 months and 6 months of eradication treatment | Day 92, Day 176 | 
| Number of days of dyspepsia drug administration | Number of days of dyspepsia drug administration after 3 months and 6 months of eradication treatment compared to baseline | Day 92, Day 176 |
Intraarticular Gold Microparticles for Hip Osteoarthritis

Study Overview
=================
Brief Summary
-----------------
In a pilot study, we recently showed that intraarticular metallic gold microparticles reduce knee osteoarthritis pain for up to two years and found associated significant proteomic changes in serum and synovial fluid within eight weeks. This study aim to evaluate the outcome after intra-articular injection of gold microparticles for hip osteoarthritis.

Detailed Description
-----------------
A cohort of 20 patients, aged ≥ 18 years, with pain ≥ 3 months, and Kellgren-Lawrence OA grade 2-4, will beincluded. Metallic gold 20 mg, 72.000 pieces, 20-40 µ-meter (Berlock-Micro-Implants, HumanGoldInject) (1) were injected into the hip joint using hyaluronic acid as the carrier. In total, we treated 24 hip joints. The primary outcome was the Western Ontario and McMaster Universities Arthritis Index (WOMAC).

Official Title
-----------------
Intraarticular Gold Microparticles for Hip Osteoarthritis - a 2-year Follow-up Pilot Study.

Conditions
-----------------
Osteoarthritis, Hip

Intervention / Treatment
-----------------
* Combination Product: Gold


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: confirmed moderate hip OA (Kellgren-Lawrence grade ≥ 2), pain for more than 3 months, and maximal pain intensity VAS (Visual Analogue Scale, 0-10) ≥ 5 during the last week Exclusion Criteria: exclusion criteria were 1) malignancy, 2) active infection and antibiotic treatment, 3) active treatment with steroids, biological or other anti-rheumatic medication, 4) history of chronic pain condition, 5) inability to comply with the protocol, and 6) inadequacy in written and spoken national language.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Combination Product: Gold|Intra articular|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| WOMAC | Western Ontario and McMaster Universities Arthritis Index | 2 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PainDetect | PainDetect | 2 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hip osteoarthritis, Intra articular gold, Outcome
Biofeedback Intervention in Rehabilitation of Adolescence With Posterior Sagittal Anorectoplasty

Study Overview
=================
Brief Summary
-----------------
most of children undergo Posterior Sagittal Anorectoplasty Complain from faecal incontinence and faecal soiling which negatively impacts the social life of these children prohibiting their participation with their bears.

Detailed Description
-----------------
most of children undergo Posterior Sagittal Anorectoplasty Complain from faecal incontinence and faecal soiling which negatively impacts the social life of these children prohibiting their participation with their bears so this study aims prevent faecal incontinence so continue life time without any interference with social life and activities

Official Title
-----------------
Biofeedback Intervention in Rehabilitation of Adolescence With Posterior Sagittal Anorectoplasty

Conditions
-----------------
Fecal Incontinence in Children

Intervention / Treatment
-----------------
* Other: Biofeedback electrical stimulation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age from 10-13 years old Reliable females Able to understand verbal commands Normal vision and hearing Exclusion Criteria: Neuromuscular or musculoskeletal disorders Behavioural disorders Psychological disorders

Ages Eligible for Study
-----------------
Minimum Age: 10 Years
Maximum Age: 13 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Sequential Assignment
Interventional Model Description: pretest post test
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Biofeedback electrical stimulation<br>Biofeedback electrical stimulation | Other: Biofeedback electrical stimulation<br>* biofeedback stimulation for faecal incontinence post Posterior Sagittal Anorectoplasty<br>* Other names: Biofeedback;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| biofeedback assessment for degree of contraction of anus and puborectalis muscle | biofeedback assessment for degree of anal contraction in cases with faecal incontinence post Posterior Sagittal Anorectoplasty | 12 weeks |
Busulfan Sample Collection Study

Study Overview
=================
Brief Summary
-----------------
Busulfan (Busulfex®) is an alkylating drug used as a conditioning regimen prior to allogeneic hematopoietic stem cell transplantation. Busulfan has wide inter- and intra-patient pharmacokinetic variability resulting in variable exposure leading to increased risk of toxicities or sub-optimal treatment outcomes. Therapeutic drug monitoring of busulfan using patient plasma samples would benefit clinicians by providing the ability to personalize the dose to achieve a target busulfan exposure.

Detailed Description
-----------------
This protocol is sponsored by Saladax Biomedical, Inc (SBI). The protocol involves the use of sodium heparin plasma sample collected from human subjects receiving intravenous busulfan treatment for the use in the development of a diagnostic test for this drug. A subset of 10 enrolled subject samples will be tested on site using an automated immunoassay MyCareTM Oncology Busulfan Assay Kit manufactured by SBI.

Official Title
-----------------
Collection of Plasma Samples Using Sodium Heparin From Subjects Undergoing Intravenous Busulfan Treatment

Conditions
-----------------
Subjects Treated With Busulfan

Intervention / Treatment
-----------------
* Diagnostic Test: MyCare Oncology Busulfan Assay Kit


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pediatric and adult female or male subjects; Current treatment with intravenous busulfan with documentation of diagnosed malignant hematologic or non-malignant disease condition requiring treatment; Adult participants must be capable of understanding and providing written informed consent, approved by an Institutional Review Board (IRB) prior to the initiation of any screening or study-specific procedures. Participants less than 18 years old must provide written assent with appropriate consent provided by legal guardian, who must be capable of understanding and providing informed consent, per Institutional Review Board (IRB) procedures, prior to the initiation of any screening or study-specific procedures. Exclusion Criteria: Unwilling or unable to follow protocol requirements or to give written informed consent; Patients receiving oral busulfan (e.g., Myleran®) treatment.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: MyCare Oncology Busulfan Assay Kit|This is a sample collection study only. Patient treatment will not be determined by the outcome of the analytical test results.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Method Comparison Study | The samples being collected according to the protocol, SBI-BSI-001, will be used to compare the quantitate determination of BSF in patient samples based on the immunoassay vs. LC-MS/MS methods . | Sample collection to take place over 1 year. Samples to be analyzed monthly. |
Real-Time Cholangioscopy Artificial Intelligence Evaluation of Biliary Strictures

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to demonstrate the feasibility and validity of a previously developed peroral cholangioscopy (POC) convolutional neural network (CNN) to determine the etiology of biliary strictures when used in real-time.

Official Title
-----------------
Real-Time Cholangioscopy Artificial Intelligence Evaluation of Biliary Strictures

Conditions
-----------------
Biliary Stricture

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥ 18 years old Anticipation that patient may undergo POC during an endoscopic retrograde cholangioscopy Pregnant patients can be included in the study. Use of the POC-CNN does not convey any new risk to the patient nor fetus. Non-English speaking subjects will be included in the study. Consent for the procedure itself is always done with the assistance of an interpreter via telephone or video. Use of the POC-CNN will be discussed with all patients via this interpreter during the procedure consent. Exclusion Criteria: Age <18 years old No indication that cholangioscopy will be performed during ERCP Prisoner

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients undergoing cholangioscopy for evaluation biliary stricture<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| POC-CNN Model AUC | Area Under the Curve (AUC) analysis for POC-CNN for classification of malignant biliary stricture | Patients will be considered negative for malignancy only with 12 months of negative follow-up or definitive negative surgical histology. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Test characteristics of POC-CNN | Sensitivity and Specificity of POC-CNN for the diagnosis of malignant biliary stricture, Sensitivity and Specificity of biliary brushings and biliary biopsies | Patients will be considered negative for malignancy only with 12 months of negative follow-up or definitive negative surgical histology. |
Safety of Antibiotic Intake During Pregnancy

Study Overview
=================
Brief Summary
-----------------
this study will be conducted to assess the knowledge of the pregnant females regarding safety of antibiotic intake ,also their attitude toward any prescribed antibiotics during their pregnancy .

Detailed Description
-----------------
this study will be conducted on pregnant females from two Arab countries to assess their knowledge and attitude toward any prescribed antibiotics while they are pregnant .Also to assess any malpractice while their intake for any antibiotics . this study is a cross sectional study that will involve a questionnaire including the three mentioned domains .

Official Title
-----------------
Safety of Antibiotic Intake During Pregnancy: Results of Questionnaire of Pregnant Women in Two Arab Countries

Conditions
-----------------
Infections

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: pregnant women at any gestational age Exclusion Criteria: pregnant women who refused to participate

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants with antibiotic-related side effects | using a questionnaire to measure the knowledge and attitude of pregnant women toward antibiotics that were taken during pregnancy and any malpractice during its intake | through study completion ,an average of one year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
antibiotics, infection